Condition
Sickle Cell Disease
Locations
Australia, United States
Start date
17/02/2025
Identifiers
Trial ID
NN7535-7807,
NCT number NCT06612268,
Eudract number Not Available
NCT number NCT06612268,
Eudract number Not Available
Summary
This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo. Which treatment the participants will get is decided by chance. Etavopivat is a new medicine and is currently being tested in other studies in addition to this one. The study will last for about 2 years.
Trial Overview:
Treatment
DRUG: Etavopivat
DRUG: Placebo
Study type
INTERVENTIONAL
Trial duration
Feb 17 2025 - Sep 22 2028
Participants
408
Phase
III
Are you eligible?
Gender
Male and female
Age
12 years and older
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.